City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
  PROFILE 
The following is a list of available studies directed by  Marianna Koczywas, MD  
Search results:  8  Clinical trial(s) found  (Page 1 of 1 )
Results per page: 25 50 100 All 1-8 Trials Jump to page:

COH Protocol Number: 16195 ClinicalTrials.gov Number: NCT02496663

Principal Investigator: Marianna Koczywas, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-77, NCI#9898: A Phase I Trial of AZD9291 and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer after Progression on a Previous EGFR Tyrosine Kinase Inhibitor

COH Protocol Number: 16177 ClinicalTrials.gov Number: NCT02860286

Principal Investigator: Marianna Koczywas, MD
Sponsor: Industrial

Title:  A Phase 2, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with Relapsed or Refractory Malignant Mesothelioma with BAP1 Loss of Function

COH Protocol Number: 15236 ClinicalTrials.gov Number: NCT02535312

Principal Investigator: Marianna Koczywas, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-76, NCI#9837: Phase I Study of TRC102 in Combination with Cisplatin and Pemetrexed in Patients with Advanced Solid Tumors, with Expansion Cohort in Mesothelioma / Phase II Study of TRC102 with Pemetrexed in Patients Refractory to Cisplatin and Pemetrexed

COH Protocol Number: 15059 ClinicalTrials.gov Number: NCT02409342

Principal Investigator: Marianna Koczywas, MD
Sponsor: Industrial

Title:  A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PDL1 Antibody) Compared with Cisplatin or Carboplatin + Pemetrexed for PD-L1-Selected Chemotherapy Naive Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

COH Protocol Number: 15032 ClinicalTrials.gov Number: NCT02258607

Principal Investigator: Marianna Koczywas, MD
Sponsor: Industrial

Title:  A Phase Ib with Expansion Study Evaluating the Efficacy and Safety of Momelotinib Combined with Trametinib in Subjects with Metastatic KRAS-mutated Non-Small Cell Lung Cancer(NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase

COH Protocol Number: 14203 ClinicalTrials.gov Number: NCT02154490

Principal Investigator: Marianna Koczywas, MD
Sponsor: Cooperative Group

Title:  SWOG S1400: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

COH Protocol Number: 14142 ClinicalTrials.gov Number: NCT02152631

Principal Investigator: Marianna Koczywas, MD
Sponsor: Industrial

Title:  A Randomized Phase 3 Study of LY2835219 Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients with Stage IV NSCLC with a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy

COH Protocol Number: 12194 ClinicalTrials.gov Number: NCT01416688

Principal Investigator: Marianna Koczywas, MD
Sponsor: Cooperative Group

Title:  SWOG S1013: A Prospective Study of Epidermal Growth Factor Receptor (HER-1/EGFR) Inhibitor -Induced Dermatalogic Toxicity: Validation of the Functional Assessment of Cancer Therapy-EGFRI 18 (FACT-EGFR 18) Questionnaire for EGFRI-Induced Skin Toxicities

 
Results per page: 25 50 100 All 1-8 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.